Inozyme Pharma's total inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. Inozyme Pharma's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Inozyme Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $0.74.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Inozyme Pharma Total Inventories Historical Data
The historical data trend for Inozyme Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Inozyme Pharma (NAS:INZY) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Inozyme Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Inozyme Pharma's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Inozyme Pharma Total Inventories Related Terms
Thank you for viewing the detailed overview of Inozyme Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INZY has been successfully added to your 